BRIEF—Gilead lifts curtain on ASCO 2023 presentations

Gilead Sciences has provided an outline of 30 abstracts it will present at America’s leading cancer conference, the annual meeting of the American Society of Clinical Oncology (ASCO).

Presentations will include final overall survival (OS) results from the Phase III TROPiCS-02 study of antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) in breast cancer.

Gilead will also present the first Phase II data evaluating Trodelvy as a potential therapy in advanced endometrial cancer.

In addition, a late-breaking oral presentation from the landmark Phase III ZUMA-7 study will highlight OS results for Yescarta (axicabtagene ciloleucel) in large B-cell lymphoma (LBCL).

Commenting on the ZUMA-7 data, global clinical development head Frank Neumann said Yescarta was “the first and only treatment in 30 years to demonstrate a statistically significant improvement in overall survival versus historical standard of care in this patient population.”

Trial updates will also be shared from ongoing studies in lung cancer, triple-negative breast cancer, ulcerative colitis and several other solid tumors.